A 14 year female patient complaint epigastric pain after meal usg normal all ppi antibiotics sporolac taken no symptometric reliefr
Reading File
Finding Sources
Finding Sources
Searching PubMed
functional dyspepsia children adolescents treatment
Finding Sources
Finding Sources
Searching PubMed
functional dyspepsia pediatric diagnosis management
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
I now have sufficient information from authoritative textbooks plus PubMed evidence. Let me compose a comprehensive clinical response.
Clinical Assessment: 14-Year-Old Female - Postprandial Epigastric Pain, PPI/Antibiotic Failure
Bottom line: This presentation is highly consistent with Functional Dyspepsia (FD) - Epigastric Pain Syndrome (EPS) by Rome IV criteria. The normal USG, failure to respond to PPIs + antibiotics + probiotics, and adolescent age all point toward a functional/motility disorder rather than structural or acid-peptic disease.
Step 1: Confirm the Diagnosis - Rome IV Criteria for Functional Dyspepsia
Per Rome IV (Sleisenger & Fordtran), FD requires all of the following for at least 3 months:
- One or more of: bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning
- No evidence of structural disease (including at endoscopy/imaging) to explain symptoms
This patient has postprandial epigastric pain + normal USG = consistent with FD. FD is subclassified:
- Postprandial Distress Syndrome (PDS): Early satiety, postprandial fullness
- Epigastric Pain Syndrome (EPS): Epigastric pain/burning - fits this patient
Step 2: Why Did She Not Respond?
| Treatment tried | Why it may have failed |
|---|---|
| PPI | PPIs help EPS slightly (relative risk ~0.77-0.88 vs placebo) but are not curative; ~30-40% response only |
| Antibiotics | H. pylori status unclear - if not tested properly, empirical antibiotics won't help FD |
| Sporolac (probiotic) | No strong evidence for FD specifically; helps IBS-type symptoms more |
| USG Normal | Rules out biliary/pancreatic disease but misses mucosal/motility pathology |
Step 3: What is MISSING in Workup?
Critical investigations NOT yet done:
-
H. pylori testing (stool antigen or UBT - not just empirical antibiotics)
- If positive and FD confirmed on EGD: H. pylori eradication can give 10-15% additional benefit over placebo
- "Test and treat" is standard for uninvestigated dyspepsia in younger patients
-
Upper GI Endoscopy (EGD) - now indicated because:
- Symptoms persisting despite adequate PPI trial (4-8 weeks)
- Needed to definitively diagnose FD (rule out peptic ulcer, eosinophilic gastritis, celiac disease, H. pylori gastritis)
- Mucosal biopsies for: celiac disease (anti-tTG IgA + duodenal biopsy), eosinophilic gastroenteritis, Crohn's disease, lymphocytic gastritis
-
Blood tests: CBC (anaemia?), ESR/CRP, serum anti-tTG IgA (celiac), blood glucose, thyroid function (TSH), liver/renal function
-
Consider in second line: Gastric emptying scintigraphy if gastroparesis suspected (nausea, vomiting prominent)
Step 4: Key Differential Diagnoses NOT to Miss in This Adolescent
| Diagnosis | Why suspect | How to confirm |
|---|---|---|
| Celiac disease | Adolescent female, GI symptoms, common & often missed | Anti-tTG IgA + duodenal biopsy |
| H. pylori gastritis | May not respond to empirical antibiotics if wrong regimen | Stool antigen or UBT (not serology alone) |
| Eosinophilic gastroenteritis | USG normal, PPI failure | EGD + biopsies |
| Peptic ulcer disease | Postprandial pain pattern | EGD |
| Gastroparesis | Motility disorder | Gastric emptying scan |
| Mesenteric adenitis | Adolescent, recurrent pain | CT abdomen if needed |
| Ovarian pathology | 14-year-old female | Pelvic USG (was abdominal USG done only?) |
| Psychological/functional | Anxiety, school stress common trigger | FD diagnosis + psychosocial assessment |
Important: USG of the abdomen may not adequately evaluate the pelvis in a 14-year-old female. A dedicated pelvic USG should be done to exclude ovarian cysts, endometriosis (rare at this age but possible).
Step 5: Management Plan (If FD Confirmed)
Non-pharmacological (first line):
- Reassurance with confident diagnosis - reduces health-seeking behavior
- Dietary advice: smaller, more frequent meals; avoid fatty/spicy foods, carbonated drinks, caffeine
- Identify and address psychosocial stressors (school, family, anxiety)
- Cognitive Behavioral Therapy (CBT) - evidence-based in adolescents
Pharmacological options for refractory FD-EPS:
| Drug | Mechanism | Dose | Evidence |
|---|---|---|---|
| PPI continued | Acid suppression | Omeprazole 20 mg OD x 4-8 wks | Modest benefit for EPS subtype |
| Prokinetic (domperidone/itopride) | Improve gastric motility | Domperidone 10 mg TDS | For PDS/mixed type; limited trial in adolescents |
| Low-dose TCA (amitriptyline) | Visceral analgesic, antinociceptive | 10-25 mg at bedtime | Beneficial in refractory FD; independent of antidepressant effect - Yamada's |
| Buspirone | 5-HT1A agonist, fundus relaxation | 5-10 mg TDS | Helps early satiety/fullness |
| H. pylori eradication | If confirmed positive | Triple therapy x 14 days | 10-15% symptom benefit |
| Mirtazapine | 5-HT3 antagonist, appetite stimulation | Low dose | Nausea/fullness predominant |
In adolescents specifically: Low-dose amitriptyline (10 mg nocte) is well-tolerated and has good evidence for functional abdominal pain in pediatric age groups.
Step 6: Red Flag Features - Refer/Investigate Urgently if Present
- Unexplained weight loss
- Dysphagia
- Recurrent vomiting
- GI bleeding / iron deficiency anaemia
- Positive family history of GI malignancy
- Nocturnal symptoms awakening from sleep
- Progressive worsening
Summary Action Plan
- Do H. pylori stool antigen test - treat if positive with proper regimen
- Upper GI endoscopy + biopsies (celiac screen, eosinophilic gastritis, H. pylori histology)
- Pelvic USG if not done
- Blood work: CBC, ESR, anti-tTG IgA, TSH, LFT, RFT
- If EGD normal → Confirm FD, initiate structured management: dietary modification + CBT + consider low-dose amitriptyline
- Gastric emptying study if nausea/vomiting is prominent or gastroparesis suspected
The most likely diagnosis is Functional Dyspepsia (Epigastric Pain Syndrome) in this adolescent, but celiac disease and H. pylori must be formally excluded before that label is applied. - Sleisenger & Fordtran, Chapter 14; Yamada's Gastroenterology, Chapter on Functional Dyspepsia
For recent pediatric evidence: A 2023 Cochrane meta-analysis (PMID 36799531) on probiotics for functional abdominal pain in children found limited evidence for benefit, supporting the decision to look beyond Sporolac. A 2025 network meta-analysis in Lancet Child & Adolescent Health (PMID 40246358) identifies psychological interventions as among the most effective treatments for pediatric functional GI disorders.
Triple therapy dose
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Here is the complete H. pylori triple therapy dosing, with all major regimens from Harrison's Principles of Internal Medicine 22E and Yamada's Textbook of Gastroenterology:
H. pylori Eradication Regimens - Full Dose Guide
Standard Triple Therapy (First Line)
Use ONLY if local clarithromycin resistance is <15% AND patient has no prior macrolide exposure
| Drug | Adult Dose | Frequency | Duration |
|---|---|---|---|
| PPI (e.g., Omeprazole 20 mg / Pantoprazole 40 mg / Rabeprazole 20 mg) | Standard or double dose | BD | 14 days |
| Clarithromycin | 500 mg | BD | 14 days |
| Amoxicillin | 1 g | BD | 14 days |
If penicillin allergic - replace Amoxicillin with Metronidazole 500 mg TDS
Pediatric doses (weight-based):
| Drug | Pediatric Dose |
|---|---|
| Omeprazole | 1-2 mg/kg/day (max 20 mg BD) |
| Clarithromycin | 7.5 mg/kg BD (max 500 mg BD) |
| Amoxicillin | 25 mg/kg BD (max 1 g BD) |
| Metronidazole (if pen-allergic) | 10 mg/kg TDS (max 500 mg) |
For this 14-year-old (assuming ~45-50 kg), standard adult doses typically apply.
Why 14 Days (Not 7)?
14-day courses improve eradication by ~5% over 7-day courses without extra adverse effects. Always prescribe 14 days - Yamada's Gastroenterology.
Other Regimens (When Triple Fails or Resistance Suspected)
| Regimen | Drugs | Dose | Duration |
|---|---|---|---|
| Bismuth Quadruple (now often preferred as 1st line) | PPI BD + Bismuth subcitrate 120-300 mg QID + Tetracycline 500 mg QID + Metronidazole 250-500 mg QID | Standard | 10-14 days |
| Concomitant (4-drug) | PPI BD + Clarithromycin 500 mg BD + Amoxicillin 1g BD + Metronidazole/Tinidazole 500 mg BD | All together | 10-14 days |
| Levofloxacin Triple (2nd line/salvage) | PPI BD + Amoxicillin 1g BD + Levofloxacin 500 mg OD | Standard | 5-7 days |
| Sequential | Days 1-5: PPI + Amoxicillin 1g BD → Days 6-10: PPI + Clarithromycin 500mg BD + Metronidazole 500mg BD | Step-wise | 10 days |
| High-dose Dual (salvage) | PPI (double dose) BD + Amoxicillin 1g TDS-QID | For rifabutin-based failure | 14 days |
Key Clinical Points
- Test before treating - use stool antigen test (SAT) or urea breath test (UBT); serology alone is unreliable for active infection
- Test for eradication - repeat UBT or SAT 4 weeks after completing therapy (stop PPI 2 weeks before)
- India context: Clarithromycin resistance is rising in urban India - consider bismuth quadruple therapy as first-line if available, or concomitant 4-drug therapy
- Avoid fluoroquinolones (levofloxacin) in children <18 years unless no alternative
- Tetracycline is contraindicated in children <8 years - avoid bismuth quadruple in young children; this patient at 14 years can receive it if needed
Harrison's 22E, Chapter on Peptic Ulcer Disease; Yamada's Gastroenterology Chapter 49
This is a shared conversation. Sign in to Orris to start your own chat.